Hemodynamic MonitoringNCT07862608
Evaluation of the UltraTrac System as a Non-Invasive Monitor of Hemodynamic Parameters
An observational study of Hemodynamic Monitoring, run by AcQumen Medical, Inc. at 1 site in United States.
Trial summary
This study will test the use of the UltraTrac™ system, a small, noninvasive device that uses electrodes on the skin and a small ultrasound sensor to provide measurements of cardiac function in a wide of subjects. Read more about this study
- Who is it for?
- Ages 2 months to 95 yearsHealthy volunteers can take part
- Conditions the study is for
- Hemodynamic Monitoring
- What is being tested?
- Noninvasive Hemodynamic Monitoring System
- Type of treatment
- Medical device
- How many people
- 400 participants
- Where
- 1 siteUnited States
- Study dates
- 27 Sep 2026to 27 Sep 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 months to 95 years
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: This study will enroll up to 400 volunteer participants ranging from 2 months to 95 years of age, representing a broad cross-section of the general population. Subjects must be generally healthy, as determined by verbal health history, and have had no hospitalizations or emergency care visits for cardiopulmonary conditions within the preceding 30 days. Participants may include individuals with or without stable cardiovascular or pulmonary conditions, provided they meet all inclusion criteria and have no active illness. Enrollment will include diverse racial and ethnic backgrounds and both pediatric and adult age groups. Subjects must be able to understand and comply with study procedures, and for minors, parental permission and age-appropriate assent are required. Individuals with pregnancy, lactation, active skin conditions at electrode placement sites, or known sensitivities to adhesives, hydrogel, or ultrasound gel will be excluded.
Who may be able to join
- Age 2 months to 95 years of age, of varying racial origins, and with or without cardiovascular or pulmonary disease.
- Generally healthy, as confirmed by verbal health history at screening.
- Parent or legal guardian provides written informed consent; subject provides assent where applicable and appropriate.
- Subject and parent/guardian are able to understand and comply with study procedures.
Who cannot join
- Participants who have had admission or a visit to an emergency room or hospital admission for a cardiovascular or pulmonary illness such as congestive heart failure or asthma, within the prior 30 days will be excluded.
- Females if lactating or pregnant, or if childbearing potential and without use of standard birth control, will be excluded.
- Active skin condition, injury, rash, or dermatitis in areas of planned electrode or ultrasound probe placement.
- Known latex or adhesive sensitivity or sensitivity to hydrogel or ultrasound coupling gel.
- Any condition that, in the opinion of the investigator, would compromise participant safety or the integrity of study data.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
AcQumen Medical
Riverside, Connecticut, 06878
Dori Jones, MSE, 8662278636, djones@acqumenmedical.com
Jenny Freeman, MD
About this study
Official title: Evaluation of the UltraTracTM System as a Non-Invasive Monitor of Hemodyamic Parameters
This study will test the use of the UltraTrac™ system, a small, noninvasive device that uses electrodes on the skin and a small ultrasound sensor to provide measurements of cardiac function in a wide of subjects. UltraTrac estimates cardiac output and other hemodynamic parameters without needles or invasive procedures.
Up to 400 generally healthy volunteers, from infants to older adults, will take part in a single study visit lasting about one hour. During the visit, study staff place small adhesive electrodes on the skin and a lightweight ultrasound sensor on the neck or thigh. The device records heart-related signals while the participant is lying down, sitting, and during simple movements such as repositioning, passive leg raise, or light exercise (like walking or pedaling in place). The study evaluates how often the UltraTrac device can collect good-quality signals and how consistent the measurements are across different ages and activity levels.
There is no direct medical benefit to participants. The risks are minimal, such as mild skin irritation from adhesive electrodes. The information collected will help improve the UltraTrac system and support future regulatory review so that noninvasive cardiac monitoring may become more widely available, especially for children and other patients who are not able to undergo invasive monitoring.
Read the detailed description
UltraTrac™ is a noninvasive monitoring system developed by AcQumen Medical, Inc. that combines impedance cardiography with carotid Doppler ultrasound to estimate stroke volume, cardiac output, and left ventricular ejection time continuously and without invasive procedures. Continuous hemodynamic monitoring is difficult in both pediatric and adult populations. UltraTrac uses surface-skin electrodes to calculate hemodynamics via impedance and integrates a miniature ultrasound sensor to address these limitations and is designed to function across a wide range of patient sizes, including infants, young children, and obese individuals.
This prospective, observational volunteer study is intended to collect systematic data on UltraTrac signal acquisition quality, measurement consistency, and device performance across age groups and activity conditions. Prior early data have been collected in patients under institutional IRB approval. This study expands evaluation to healthy volunteers to support device development, algorithm refinement, and future regulatory submissions, including a planned 510(k) application.
Each participant will complete a single study visit lasting approximately one hour. During the visit, study personnel place standard adhesive electrodes and a small ultrasound sensor on the skin. The device will record impedance and ultrasound signals while the participant is lying down, seated, and/or during structured movement conditions. These may include natural repositioning, passive leg raise, and simple activity such as walking in place or pedaling a small stationary bicycle. Up to ten measurement sets may be collected per condition, and ultrasound signal strength will be documented using the device's integrated signal-quality display. Some participants may return for additional visits to support intra-subject variability analysis.
The study focuses on evaluating whether UltraTrac can reliably obtain usable signals and produce consistent hemodynamic measurements under real-world conditions. Because this is an exploratory study, analyses emphasize descriptive statistics, signal-to-noise characteristics, and measurement precision. Hemodynamic values are summarized to characterize expected ranges across ages and activity states, but no clinical interpretation will be performed. UltraTrac data will not be used for diagnosis or treatment.
The device uses FDA-cleared materials, including standard monitoring electrodes and ultrasound gel. Risks are minimal and primarily related to mild skin irritation or discomfort from adhesive removal. Movement-based activities are limited to each participant's comfort level, and individuals with recent cardiopulmonary illness are excluded to reduce the risk of presyncope. No electrical current beyond standard bioimpedance monitoring levels is delivered.
Data collected from this study will help determine how well UltraTrac performs across a broad population, inform improvements to signal processing and algorithms, and support future clinical studies in acute-care environments. The long-term goal is to provide clinicians with a noninvasive, continuous tool for assessing cardiac function and detecting early hemodynamic compromise.
- Conditions
- Hemodynamic Monitoring
- Being tested
- Noninvasive Hemodynamic Monitoring System
- Keywords
- Hemodynamics, Cardiovascular Physiology, Cardiac Output, Stroke Volume, Ventricular Function, Left, Impedance Cardiography, Ultrasonography, Doppler, Monitoring, Physiologic, Volunteer, Pediatric Monitoring, Monitoring, Signal Processing
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Noninvasive Hemodynamic Monitoring SystemDevice
Also called UltraTrac, Impedance Cardiography
This study involves the use of a noninvasive hemodynamic monitoring system that integrates impedance cardiography with Doppler ultrasound to measure cardiac function. The system uses standard adhesive electrodes placed on the skin and a small ultrasound sensor positioned over the carotid or femoral artery. During each measurement period, the system collects impedance waveforms and ultrasound timing signals to estimate stroke volume, cardiac output, and left ventricular ejection time. Data are recorded while participants are at rest and during simple movement conditions to evaluate signal acquisition quality, measurement precision, and device performance. The UltraTrac is used only for physiologic monitoring and data collection. Study data are not used to deliver therapy, influence clinical care, or provide diagnostic information to participants or clinicians.
| Study group | Role | What they receive |
|---|---|---|
| Healthy Volunteer Cohort | This cohort includes generally healthy volunteer participants ranging from infants to older adults who complete a single study visit involving noninvasive monitoring with the UltraTrac™ system. All participants undergo a structured measurement protocol, which includes placement of standard adhesive electrodes and a small Doppler ultrasound sensor, followed by resting, and for some participants, movement-based measurement conditions. UltraTrac collects impedance and ultrasound signals to evaluate device performance, signal acquisition quality, and measurement consistency. No clinical interventions are performed, and device output is used solely for research and development purposes. Receives: Device: Noninvasive Hemodynamic Monitoring System |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of successful waveform acquisition and adequate signal to noise characteristics
Successful ICG waveform acquisition rate as determined by counts and proportions of subjects; adequate ultrasound signal strength summarized descriptively; adequate ICG and ultrasound signal to noise characteristics summarized descriptively
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Oct 2026
- Study start27 Sep 2026 (estimated)
- Primary completion27 Sep 2028 (estimated)
- Study completion27 Sep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hemodynamic MonitoringStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AcQumen Medical, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07862608
- Sponsor's protocol ID
- AQM-UT-001
- Status last verified
- Oct 2026
- First submitted
- 24 Sep 2026
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the UltraTracTM System as a Non-Invasive Monitor of Hemodyamic Parameters
- ClinicalTrials.gov ID
- NCT07862608
- Acronym / sponsor ID
- AQM-UT-001
- Conditions
- Hemodynamic Monitoring
- Keywords
- Hemodynamics, Cardiovascular Physiology, Cardiac Output, Stroke Volume, Ventricular Function, Left, Impedance Cardiography, Ultrasonography, Doppler, Monitoring, Physiologic
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- AcQumen Medical, Inc.Industry (pharma, biotech, devices)
- Study start
- 27 Sep 2026 (estimated)
- Primary completion
- 27 Sep 2028 (estimated)
- Study completion
- 27 Sep 2028 (estimated)
- First posted
- 7 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will test the use of the UltraTrac™ system, a small, noninvasive device that uses electrodes on the skin and a small ultrasound sensor to provide measurements of cardiac function in a wide of subjects. UltraTrac estimates cardiac output and other hemodynamic parameters without needles or invasive procedures.
Up to 400 generally healthy volunteers, from infants to older adults, will take part in a single study visit lasting about one hour. During the visit, study staff place small adhesive electrodes on the skin and a lightweight ultrasound sensor on the neck or thigh. The device records heart-related signals while the participant is lying down, sitting, and during simple movements such as repositioning, passive leg raise, or light exercise (like walking or pedaling in place). The study evaluates how often the UltraTrac device can collect good-quality signals and how consistent the measurements are across different ages and activity levels.
There is no direct medical benefit to participants. The risks are minimal, such as mild skin irritation from adhesive electrodes. The information collected will help improve the UltraTrac system and support future regulatory review so that noninvasive cardiac monitoring may become more widely available, especially for children and other patients who are not able to undergo invasive monitoring.
Detailed description
UltraTrac™ is a noninvasive monitoring system developed by AcQumen Medical, Inc. that combines impedance cardiography with carotid Doppler ultrasound to estimate stroke volume, cardiac output, and left ventricular ejection time continuously and without invasive procedures. Continuous hemodynamic monitoring is difficult in both pediatric and adult populations. UltraTrac uses surface-skin electrodes to calculate hemodynamics via impedance and integrates a miniature ultrasound sensor to address these limitations and is designed to function across a wide range of patient sizes, including infants, young children, and obese individuals.
This prospective, observational volunteer study is intended to collect systematic data on UltraTrac signal acquisition quality, measurement consistency, and device performance across age groups and activity conditions. Prior early data have been collected in patients under institutional IRB approval. This study expands evaluation to healthy volunteers to support device development, algorithm refinement, and future regulatory submissions, including a planned 510(k) application.
Each participant will complete a single study visit lasting approximately one hour. During the visit, study personnel place standard adhesive electrodes and a small ultrasound sensor on the skin. The device will record impedance and ultrasound signals while the participant is lying down, seated, and/or during structured movement conditions. These may include natural repositioning, passive leg raise, and simple activity such as walking in place or pedaling a small stationary bicycle. Up to ten measurement sets may be collected per condition, and ultrasound signal strength will be documented using the device's integrated signal-quality display. Some participants may return for additional visits to support intra-subject variability analysis.
The study focuses on evaluating whether UltraTrac can reliably obtain usable signals and produce consistent hemodynamic measurements under real-world conditions. Because this is an exploratory study, analyses emphasize descriptive statistics, signal-to-noise characteristics, and measurement precision. Hemodynamic values are summarized to characterize expected ranges across ages and activity states, but no clinical interpretation will be performed. UltraTrac data will not be used for diagnosis or treatment.
The device uses FDA-cleared materials, including standard monitoring electrodes and ultrasound gel. Risks are minimal and primarily related to mild skin irritation or discomfort from adhesive removal. Movement-based activities are limited to each participant's comfort level, and individuals with recent cardiopulmonary illness are excluded to reduce the risk of presyncope. No electrical current beyond standard bioimpedance monitoring levels is delivered.
Data collected from this study will help determine how well UltraTrac performs across a broad population, inform improvements to signal processing and algorithms, and support future clinical studies in acute-care environments. The long-term goal is to provide clinicians with a noninvasive, continuous tool for assessing cardiac function and detecting early hemodynamic compromise.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Healthy Volunteer Cohort | – | Device: Noninvasive Hemodynamic Monitoring SystemThis cohort includes generally healthy volunteer participants ranging from infants to older adults who complete a single study visit involving noninvasive monitoring with the UltraTrac™ system. All participants undergo a structured measurement protocol, which includes placement of standard adhesive electrodes and a small Doppler ultrasound sensor, followed by resting, and for some participants, movement-based measurement conditions. UltraTrac collects impedance and ultrasound signals to evaluate device performance, signal acquisition quality, and measurement consistency. No clinical interventions are performed, and device output is used solely for research and development purposes. |
Who may qualify
- Ages
- 2 months to 95 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- This study will enroll up to 400 volunteer participants ranging from 2 months to 95 years of age, representing a broad cross-section of the general population. Subjects must be generally healthy, as determined by verbal health history, and have had no hospitalizations or emergency care visits for cardiopulmonary conditions within the preceding 30 days. Participants may include individuals with or without stable cardiovascular or pulmonary conditions, provided they meet all inclusion criteria and have no active illness. Enrollment will include diverse racial and ethnic backgrounds and both pediatric and adult age groups. Subjects must be able to understand and comply with study procedures, and for minors, parental permission and age-appropriate assent are required. Individuals with pregnancy, lactation, active skin conditions at electrode placement sites, or known sensitivities to adhesives, hydrogel, or ultrasound gel will be excluded.
Key inclusion criteria (4 listed)
- Age 2 months to 95 years of age, of varying racial origins, and with or without cardiovascular or pulmonary disease.
- Generally healthy, as confirmed by verbal health history at screening.
- Parent or legal guardian provides written informed consent; subject provides assent where applicable and appropriate.
- Subject and parent/guardian are able to understand and comply with study procedures.
Key exclusion criteria (5 listed)
- Participants who have had admission or a visit to an emergency room or hospital admission for a cardiovascular or pulmonary illness such as congestive heart failure or asthma, within the prior 30 days will be excluded.
- Females if lactating or pregnant, or if childbearing potential and without use of standard birth control, will be excluded.
- Active skin condition, injury, rash, or dermatitis in areas of planned electrode or ultrasound probe placement.
- Known latex or adhesive sensitivity or sensitivity to hydrogel or ultrasound coupling gel.
- Any condition that, in the opinion of the investigator, would compromise participant safety or the integrity of study data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Noninvasive Hemodynamic Monitoring SystemAlso: UltraTrac, Impedance CardiographyThis study involves the use of a noninvasive hemodynamic monitoring system that integrates impedance cardiography with Doppler ultrasound to measure cardiac function. The system uses standard adhesive electrodes placed on the skin and a small ultrasound sensor positioned over the carotid or femoral artery. During each measurement period, the system collects impedance waveforms and ultrasound timing signals to estimate stroke volume, cardiac output, and left ventricular ejection time. Data are recorded while participants are at rest and during simple movement conditions to evaluate signal acquisition quality, measurement precision, and device performance. The UltraTrac is used only for physiologic monitoring and data collection. Study data are not used to deliver therapy, influence clinical care, or provide diagnostic information to participants or clinicians. | Device | Healthy Volunteer Cohort |
Primary outcome
Rate of successful waveform acquisition and adequate signal to noise characteristics
Time frame: Baseline
Successful ICG waveform acquisition rate as determined by counts and proportions of subjects; adequate ultrasound signal strength summarized descriptively; adequate ICG and ultrasound signal to noise characteristics summarized descriptively
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2026.
Related trials for Hemodynamic Monitoring
RecruitingObservational study
Comparison of Hemodynamic Responses During Anesthesia Induction Using Eleveld and Schnider
Spinal (Fusion) Surgery, Total Intravenous Anesthesia
Recruiting
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Heart Failure, Heart Diseases
Not yet recruitingObservational study
Ultrasound-Calibrated Pulse Contour Cardiac Output Monitoring: Value and Accuracy in Hemodynamic Care
Sepsis, Circulatory Instability
Not yet recruiting
UltraTrac for Cardiac Output Monitoring in Congenital Heart Disease
Congenital Heart Disease, Cardiac Output
Not yet recruiting
ASSISTED FLUID MANAGEMENT SYSTEM IN KIDENY TRANSPLANTATION
Kidney Transplant
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hemodynamic Monitoring, run by AcQumen Medical, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of successful waveform acquisition and adequate signal to noise characteristics (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.